Donor Hematopoietic Stem and Progenitor Cell therapy (University Of California, Los Angeles)

N/A

Report date: 2026/03/13 20:02:36

Base Information

Drug NameDonor Hematopoietic Stem and Progenitor Cell therapy (University Of California, Los Angeles)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived

Mechanisms of ActionStem cell replacements

TargetsUpdating

Therapy Area/IndicationsImmune System DiseasesEnd Stage Liver DiseaseRejection of liver transplantation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of California, Los Angeles

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, Los Angeles

Inactive CompaniesN/A

Active IndicationsEnd Stage Liver DiseaseRejection of liver transplantation

Inactive IndicationsImmune System Diseases

Other Information

ATC CodeN/A